Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for Quality of Life in Autism Spectrum Disorders
NCT02903030Phase 1Completed
- Sponsor
- The Ohio State University
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Visbiome in Autism Spectrum Disorder (ASD), anxiety disorder and Digestive tract dysfunction (2 arms), sponsored by The Ohio State University. Primary endpoint: Pediatric Quality of Life Inventory Gastrointestinal Module at 8 weeks. Started Aug 2016; status: completed.
02
Drugs
Visbiome
03
Conditions
Autism Spectrum Disorder (ASD)anxiety disorderDigestive tract dysfunction
Beyond the preview
Go deeper on NCT02903030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903030.